We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Enoxaparin Treatment Followed by Rivaroxaban for the Treatment of Acute Lower Limb Venous Thromboembolism.
- Authors
Wolosker, Nelson; Varella, Andrea Y. M.; Fukuda, Juliana M.; Teivelis, Marcelo; Kuzniec, Sergio; Krutman, Mariana; Guerra, João C. de C.; Ramacciotti, Eduardo
- Abstract
Rivaroxaban is a target-specific oral anticoagulant approved for the treatment of venous thromboembolism (VTE). On its major clinical trials, treatment was initiated directly with a 3-week dose of oral 15 mg twice daily followed by 20 mg every day for at least 3 months. We retrospectively evaluated an initial therapy for confirmed VTE with 1 to 18 days of enoxaparin (1 mg/kg twice daily parenteral) followed by oral rivaroxaban 20 mg every day. Of 49 patients, we found no symptomatic recurrence, no major bleeding, and only 1 clinically relevant nonmajor bleeding. We concluded in this pilot study that it is safe and effective to treat patients with enoxaparin course followed directly by a dose of 20 mg of rivaroxaban.
- Publication
Clinical & Applied Thrombosis/Hemostasis, 2016, Vol 22, Issue 4, p377
- ISSN
1076-0296
- Publication type
Article
- DOI
10.1177/1076029615621999